NCT03158103View on ClinicalTrials.gov

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 15, 2017

Primary Completion Date

April 28, 2021

Study Completion Date

April 28, 2021

Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
DRUG

MEK162

MEK162 at 30mg twice daily

DRUG

Pexidartinib

pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (2)

Array BioPharma
Plexxikon
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

collaborator

Plexxikon

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER